Testing skin reactions to biological cancer drugs in patients with cancer
Tests skin reactions to biotherapy drugs in adults with certain cancers.
Plain-language title generated from the registry record
Registry title: Evaluation of Skin Tests in Biotherapy Allergies
Key facts
- Where
- Angers, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are treated with one of seven named biotherapy drugs and have had at least two injections without a suspected allergic reaction. It studies skin tests for biotherapy allergies.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Earlier treatment
- Must be treated with one of these biotherapies: Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg or Cemiplimab 3500 mg. Must have had at least two injections without suspected allergic side effects. If taking systemic corticosteroids or H1 antihistamines, they must be stoppable at least one week before the tests. Inhaled corticosteroids are allowed.
Main reasons for not taking part
- Skin lesions, such as psoriasis or eczema, that could affect the reading of skin tests
- Poor understanding of the French language
- Pregnancy or breastfeeding
- Being in detention by judicial or administrative decision
- Being under a legal protection measure
Read by machine on 12 November 2026.
Where in France
- CHU AngersAngers, FranceContact: Martine MORISSETTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Angers
- Trial code
- NCT06971848
- Record updated
- 18 June 2026
- Original description
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.Read full original descriptionShow less
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases. In recent years, these biotherapies have notably emerged in the treatment of cancers and hematologic disorders. As such, most patients with cancers or hematologic diseases will likely receive a biotherapy as part of their care pathway.
These biotherapies are associated with various side effects, including hypersensitivity or allergic reactions, which are often poorly characterized in clinical trials. These reactions manifest as symptoms without specific dermatologic or allergologic semiology (such as itching, erythema, shortness of breath, sometimes digestive issues, or discomfort, and in some cases, an anaphylactic reaction).
Unlike other treatments, such as antibiotics and neuromuscular blockers, there are currently no guidelines on the concentrations to use in skin tests for biotherapies. We propose conducting prospective clinical research to scientifically establish the concentrations to be used when investigating hypersensitivity to a biotherapy, in line with best practice recommendations for drug skin testing.
Inclusion: Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects; Subjects covered by or having the rights to medical care assurance; Written informed consent obtained from subject; If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).
Exclusion: Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests; Poor understanding of the French language; Pregnancy, breastfeeding; Persons in detention by judicial or administrative decision; Person admitted to a health or social establishment for purposes other than research; Person subject to a legal protection measure.